In this exclusive interview, Walter Ferlin (Novimmune’s Head of Exploratory Science and Translational Medicine) discusses why the CD47/SIRPα Checkpoint is so exciting and highlights the conversations that need to happen now for this field to accelerate.

Click here to download your copy.